Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
Yosuke Kawashima(Sendai Kousei Hospital), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Haruhiro Saito(Kanagawa Prefectural Hospital Organization), Naoki Furuya(St. Marianna University School of Medicine), Kana Watanabe(Miyagi Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Shunichiro Iwasawa(Chiba University), Yoshio Tsunezuka(Ishikawa Prefectural Central Hospital), Ou Yamaguchi(Saitama Medical University), Morihito Okada(Hiroshima University Hospital), Kozo Yoshimori(Fukujuji Hospital), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Masahiro Seike(Nippon Medical School), Koichi Azuma(Kurume University), Futoshi Kurimoto(Saitama Cancer Center), Yukari Tsubata(Shimane University), Yuka Fujita(Asahikawa Medical University), Hiromi Nagashima(Iwate Medical University), Gyo Asai(Aichi Cancer Center), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Masaki Miyazaki(Suita Municipal Hospital), Koichi Hagiwara(Jichi Medical University), Toshihiro Nukiwa(Tohoku University), Satoshi Morita(Kyoto University), Kunihiko Kobayashi(Saitama Medical University), Makoto Maemondo(Iwate Medical University)
Institutional Repositories DataBase (IRDB)
January 1, 2022
Cited by 109
Abstract
Related Papers
No related papers found
Powered by citation graph analysis